Phase I Study of AZD5363 + Olaparib + Durvalumab in Patients With Advanced or Metastatic Solid Tumor Malignancies

STATUS

Recruiting
End date

Dec 31, 2023
participants needed

40
sponsor

National University Hospital, Singapore

Updated on 22 January 2021

See if I qualify

Summary

This is a Phase 1 dose-escalation study to evaluate the safety and tolerability of combination treatment of AZD5363 + Olaparib + Durvalumab and to determine the RP2D in patients with advanced or metastatic solid tumor malignancies.

The purpose of this trial is to determine if combination treatment of drugs, Olaparib, AZD5363 and Durvalumab has beneficial effects in advanced or metastatic cancers and to determine the effects it has on patients and their cancer.

Primary Objectives

To evaluate the safety and tolerability of combination treatment AZD5363 + Olaparib + Durvalumab and determine the Maximum Tolerated Dose (MTD), Dose-Limiting Toxicities (DLTs), and Recommended Phase 2 Dose (RP2D) for patients with advanced or metastatic solid tumor malignancies.

Secondary Objectives

To determine the pharmacodynamics (PDn) of combination treatment AZD5363 + Olaparib + Durvalumab in patients with advanced or metastatic solid tumor malignancies
To describe anti-tumor response using immune RECIST of combination treatment AZD5363 + Olaparib + Durvalumab in patients with advanced or metastatic solid tumor malignancies

Exploratory Objectives

To evaluate anti-tumour response using RECIST v1.1 for combination treatment AZD5363 + Olaparib + Durvalumab in patients with advanced or metastatic solid tumor malignancies
To explore molecular correlates of the relationship between mutations in Akt/ PIK3CA/PTEN pathway and response to AZD5363 +Olaparib+ Durvalumab
To understand the role of tumour microenvironment in regulation of intratumoral immune regulators (i.e. T-regulatory cells) in improving response to Durvalumab
To understand the role of AZD5363 as an immunomodulator
To evaluate the role of PD-1 and PDL-1 immunohistochemical and tumour MMR status in predicting response to immune check point inhibitors.

Description

This study is divided into 3 different periods: Screening, Treatment, and End of Treatment Before taking the treatment, patients will have some tests and procedures done to make sure they are eligible for the study (Screening). Then they will enter the Treatment period, where Durvalumab, Olaparib and AZD5363 will be administered to them. If they stop taking your study medication for any reason, an End of Treatment visit will be conducted within 30 days after the last doze of study medication.

Screening Assessment:

Written Informed Consent
Inclusion/Exclusion Criteria
Complete Medical History
Prior therapies and PFS on last anti-cancer therapy
Complete Physical Examination amp; ECOG
Standard Clinical Neurologic Examination
BSA
Weight
Blood Pressure, Pulse and Temperature
Oxygen Saturation (Pulse Oximetry)
12-lead Electrocardiogram
HbA1c and fasting glucose
Serum Chemistry (renal panel 2) amp; Serum Troponin Level
Amylase and lipase
Liver function test
Serum Pregnancy Test (for women of childbearing potential)
Thyroid function test including TSH and free T4
Coagulation Parameters
Chest X-ray (if clinically indicated)
CBC with Differential
CT or MRI Scan Tumor Measurement
PET-CT/PET-MRI Scan Tumor Measurement (optional)
Transthoracic Echo/ MUGA
Baseline Symptoms
Concomitant Medication Assessments
Tumor Biopsy
Fasting lipids
Assessment for hepatitis B surface antigen, hepatitis C antibodies and HIV antibodies
Urinalysis

Run-in Period (Day -14 until Day 0)

Complete or Symptom Directed Physical Examination amp; ECOG
Standard Clinical Neurologic Examination
BSA
Weight
Blood Pressure, Pulse and Temperature
12-lead Electrocardiogram
Serum Chemistry (renal panel 2)
Serum Troponin Level
Coagulation Parameters
Liver panel including amylase and lipase
CBC with Differential
Oxygen Saturation (Pulse Oximetry)
Drug Administration only for AZD5363
Pharmacodynamics (PDn) blood
AE Assessments
Concomitant Medication Assessments

Cycle 1 (every week)

Complete or Symptom Directed Physical Examination amp; ECOG
Standard Clinical Neurologic Examination
BSA
Weight
Blood Pressure, Pulse and Temperature
HbA1c ( To be performed on cycle 1 day 1and every 12 week thereafter)
12-lead Electrocardiogram
Serum Chemistry (renal panel 2)
Serum Troponin Level
Coagulation Parameters
Liver panel including amylase and lipase
CBC with Differential
Thyroid Stimulating Hormone (TSH), ACTH (only every 4 weeks, D1 of every cycle)
Oxygen Saturation (Pulse Oximetry)
Drug Administration
Pharmacodynamics (PDn)
AE Assessments
Concomitant Medication Assessments
Urinalysis

Cycle 2 and Cycle 3 (every 2 weeks)

Complete or Symptom Directed Physical Examination amp; ECOG
Standard Clinical Neurologic Examination
BSA
Weight
Blood Pressure, Pulse and Temperature
12-lead Electrocardiogram
Serum Chemistry (renal panel 2)
Liver panel including amylase and lipase
Serum Troponin Level
Coagulation Parameters
CBC with Differential
Oxygen Saturation (Pulse Oximetry)
Drug Administration
Pharmacodynamics (PDn) blood (Cycle 2 Day 1)
AE Assessments
*CT or MRI Scan Tumor Measurement (end of Cycle 2every 8 weeks in the last week of the cycle)
Concomitant Medication Assessments
Fasting lipids
Urinalysis
Transthoracic Echo/ MUGA (only if indicated)

Cycle 4 and Beyond (every 4 weeks)

Complete or Symptom Directed Physical Examination amp; ECOG
Weight
Blood Pressure, Pulse and Temperature
Standard Clinical Neurologic Examination
Oxygen Saturation (Pulse Oximetry)
12-lead Electrocardiogram
Transthoracic Echo/ MUGA (only at C4D1)
Fasting lipids
Serum Chemistry (renal panel 2)
Serum Troponin Level
Thyroid Stimulating Hormone (TSH), ACTH
Coagulation Parameters
CBC with Differential
*CT or MRI Scan Tumor Measurement (end of Cycle 4 and every 8 weeks thereafter)
Drug Administration
*PET-CT/PET-MRI Scan Tumor Measurement (optional) (every 8 weeks)
AE Assessments
Concomitant Medication Assessments
Transthoracic Echo/ MUGA (only if indicated)

Final Visit

Complete Physical Examination amp; ECOG
Weight
Blood Pressure, Pulse and Temperature
Standard Clinical Neurologic Examination
Oxygen Saturation (Pulse Oximetry)
12-lead Electrocardiogram and troponin level
Transthoracic Echo/ MUGA
Fasting lipids
Serum Chemistry
Coagulation Parameters
CBC with Differential
Thyroid Stimulating Hormone (TSH)
AE assessments
Concomitant Medication Assessment

Details

Condition	Solid Tumor, Adult
Treatment	AZD5363+Olaparib+Durvalumab
Clinical Study Identifier	NCT03772561
Sponsor	National University Hospital, Singapore
Last Modified on	22 January 2021

How understandable was the trial content above?

Hard to understand

Easy to understand

Eligibility		Yes	No	Not Sure
Inclusion Criteria
	All patients must sign an informed consent in accordance with local institutional guidelines
	Age >= 21
	Histologically confirmed advanced or metastatic solid tumors who have radiological evidence of progressive disease on study entry and at least 2 measurable lesions, that is deemed unlikely to benefit from further conventional therapy, or for which no standard therapy is available. Although optional, where practicable and safe, all effort should be made by the investigator to obtain serial tumour biopsies from patients enrolled
	Provision of an archived tumour tissue block (or at least 10 newly cut unstained slides) where such samples exist in a quantity sufficient to allow for analysis
	Any number of prior chemotherapy regimens will be allowed and may include biologics
	Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1
	Patients must have adequate bone marrow function and organ function within 2 weeks of study treatment
	Adequate hematologic function defined as
	(i) platelets >= 100 x 109/L in dose escalation phase, (ii) hemoglobin >= 6.21
	mmol/L or 10 g/dL, (iii) ANC >= 1.5 x 109/L, (iv) WBC >= 3.0 x 109/L. Up to 5%
	deviation is tolerated. Transfusions and growth factors are allowed prior to
	and throughout the study
	Hepatic function: bilirubin < 1.5 times the upper limit of normal (ULN), ALT and AST < 2.5 times ULN. For patients with hepatic metastasis ALT and AST < 5 times ULN is permitted. Up to 10% deviation is acceptable
	Adequate renal function: estimated creatinine clearance of >= 60 mL/min, calculated using the formula of Cockcroft and Gault: (140-Age) Mass (kg)/(72 creatinine mg/dL); multiply by 0.85 if female
	Amylase and lipase <= 1.5 x ULN
	Alkaline phosphatase limit <= 2.5 x ULN (<= 5 x ULN for patients with liver involvement of their cancer)
	International normalization ratio (INR) (if not on anticoagulation therapy) and partial thromboplastin time (PTT) <= 1.5 x ULN
	Normal TSH and ACTH 8. Females of childbearing potential who are sexually active with a non sterilized male partner must use at least 2 highly effective method of contraception from the time of screening and must agree to continue using such precautions for 180 days after the last dose of durvalumab + any drug combination therapy or 90 days after the last dose of durvalumab monotherapy. Non-sterilized male partners of a female patient must use male condom plus spermicide throughout this period. Cessation of birth control after this point should be discussed with a responsible physician. Not engaging in sexual activity for the total duration of the drug treatment and the drug washout period is an acceptable practice; however, periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of birth control. Female subjects should also refrain from breastfeeding throughout this period. Acceptable methods of contraception are as below
	Established use of oral, injected or implanted hormonal methods of contraception
	Placement of an intrauterine device or intrauterine system
	Barrier methods of contraception: condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository
	Male partner sterilisation (with the appropriate post-vasectomy documentation of the absence of sperm in the ejaculate)
	True abstinence
	It is not known whether AZD5363 has the capacity to affect the metabolism of hormonal contraceptives, so hormonal contraception should also be combined with a barrier method of contraception or patients must have evidence of non-child-bearing potential by fulfilling one of the following criteria at
	screening
	Post-menopausal: defined as aged more than 50 years and amenorrhoeic for at least 12 months following cessation of all exogenous hormonal treatments
	Documentation of irreversible surgical sterilisation by hysterectomy, bilateral oophorectomy or bilateral salpingectomy, but not tubal ligation 9. Non-sterilized males who are sexually active with a female partner of childbearing potential must use a male condom plus spermicide from screening through 180 days after receipt of the final dose of durvalumab + any drug combination therapy or 90 days after receipt of the final dose of durvalumab monotherapy. Not engaging in sexual activity is an acceptable practice; however, occasional abstinence, the rhythm method, and the withdrawal method are not acceptable methods of contraception. Male patients are required to use barrier methods of contraception and refrain from sperm donation throughout the study and for 180 days after the last dose of study drug. Male patients wishing to father children should be advised to arrange for freezing of sperm samples prior to the start of study treatment. Breastfeeding women are also excluded from study entry. 10. At time of registration, if the patient has had previous treatment it must have been at least 4 weeks since major surgery or radiation therapy; four weeks from any other previous anti-cancer therapy including biologics. Patients must have recovered from their treatment-related events to <=G1 with the exception of alopecia and neuropathy (<= G2 sufficient). 11. Life expectancy greater than 12 weeks 12. Patients must weigh at least 30kg 13. Patients previously treated on check point inhibitor or PARP inhibitor monotherapy will be allowed on study
Exclusion Criteria
	Patients with significant medical illness that in the investigator's opinion cannot be adequately controlled with appropriate therapy or would compromise the patient's ability to tolerate this therapy
	Radiation (except planned or ongoing palliative radiation to bone outside of the region of measurable disease) <= 3 weeks prior to starting first dose of study medication
	Participation in another clinical study with an investigational product (IP) within 30 days of the first dose of AZD5363 or matching placebo.Treatment with any of the
	following
	Nitrosourea or mitomycin C within 6 weeks of the first dose of study treatment
	Any investigational agents or study drugs from a previous clinical study within 30 days of the first dose of study treatment (<= 4 weeks for previous PD-1/PD-L1)
	Any other chemotherapy, immunotherapy or anticancer agents within 3 weeks of the first dose of study treatment, except hormonal therapy with LHRH analogues for medical castration in patients with prostate cancer, which are permitted
	Potent inhibitors or inducers or substrates of CYP3A4 or substrates of CYP2D6 within 2 weeks before the first dose of study treatment (3 weeks for St John's Wort )
	Uncontrolled hypertension or controlled hypertension (<140/90) on more than 3 antihypertensive agents
	Clinically significant abnormalities of glucose metabolism as defined by any of the
	following
	Diabetes mellitus type I
	Fasting plasma glucose [fasting is defined as no calorific intake for at least 8 hours]: (i) >= 7.0mmol/L (126 mg/dL) for those patients without a pre-existing diagnosis of Type 2 diabetes mellitus (ii) >= 9.3 mmol/L (167mg/dL) for those patients with a pre-existing diagnosis of Type 2 diabetes mellitus (iii) Glycosylated haemoglobin (HbA1C) >=8.0% (63.9 mmol/mol). (iv) Requirement for insulin or more than two oral hypoglycaemic medications for routine diabetic management and control
	Major surgical procedure within the last 28 days
	Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease [eg, colitis or Crohn's disease], diverticulitis [with the exception of diverticulosis], systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome [granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc]). The following are exceptions to this
	criterion
	Subjects with vitiligo or alopecia
	Subjects with hypothyroidism (eg, following Hashimoto syndrome) stable on hormone replacement
	Any chronic skin condition that does not require systemic therapy
	Subjects without active disease in the last 5 years may be included but only after consultation with the study physician
	Subjects with celiac disease controlled by diet alone
	Any of the following cardiac criteria
	Mean resting corrected QT interval (QTc) >470 msec obtained from 3 consecutive ECGs
	Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG eg, complete left bundle branch block, third degree heart block
	Any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, hypokalaemia, potential for torsades de pointes, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age or any concomitant medication known to prolong the QT interval
	Experience of any of the following procedures or conditions in the preceding 6 months: coronary artery bypass graft, angioplasty, vascular stent, myocardial infarction, angina pectoris, congestive heart failure NYHA Grade >=2
	Uncontrolled hypotension - SBP <90 mmHg and/or DBP <50 mmHg
	Cardiac ejection fraction outside institutional range of normal or <50% (whichever is higher) as measured by echocardiogram (or MUGA scan if an echocardiogram cannot be performed or is inconclusive).Left ventricular ejection fraction (LVEF) below lower limit of normal for site
	Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, known immunodeficiency syndrome, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, interstitial lung disease (history of interstitial lung disease will also be excluded), serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring AEs or compromise the ability of the patient to give written informed consent
	Proteinuria 3+ on dipstick analysis or >500 mg/24 hours
	Sodium or potassium levels > CTCAE v4.1 grade 1
	Current or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab. The following are exceptions to this criterion
	Intranasal, inhaled, topical steroids, or local steroid injections (eg, intra articular injection)
	Systemic corticosteroids at physiologic doses not to exceed <<10 mg/day>> of prednisone or its equivalent
	Steroids as premedication for hypersensitivity reactions (eg, CT scan premedication)
	Female subjects who are pregnant or breastfeeding or male or female subjects of reproductive potential who are not willing to employ effective birth control from screening to 90 days after the last dose of durvalumab monotherapy
	Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients
	History of allogeneic organ transplant
	Known history of previous clinical diagnosis of tuberculosis
	Active infection including tuberculosis (clinical evaluation that includes clinical history, physical examination and radiographic findings, and TB testing in line with local practice), hepatitis B (known positive HBV surface antigen (HBsAg) result), hepatitis C, or human immunodeficiency virus (positive HIV 1/2 antibodies). Patients with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody [anti-HBc] and absence of HBsAg) are eligible. Patients positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA
	Renal failure requiring haemodialysis or peritoneal dialysis
	Clinically unstable, active infection requiring systemic antibiotics
	Concurrent cancer (except non-melanoma skin cancer or carcinoma in-situ of the cervix), unless in complete remission and off all therapy for that disease for a minimum of 3 years
	Patients with significantly diseased or obstructed gastrointestinal tract, malabsorption, uncontrolled vomiting or diarrhea or inability to swallow oral medications
	Patients with serious psychiatric or medical conditions that could interfere with treatment
	Patients with prior MDS/ AML
	Require therapeutic doses of anti-coagulation with warfarin or warfarin derivatives. However, treatment with low molecular weight heparin (LMWH) is allowed
	Brain metastases or spinal cord compression unless asymptomatic, treated and stable off steroids and anti-convulsants for at least 1 month prior to entry into the study
	Concurrent therapy with approved or investigational anticancer therapeutics
	Receipt of live attenuated vaccination within 30 days prior to study entry

How to participate?

Step 1 Connect with a study center

Select a site
Send a message

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Primary Contact

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Phase I Study of AZD5363 + Olaparib + Durvalumab in Patients With Advanced or Metastatic Solid Tumor Malignancies